Pharmaceuticals and Personal Care Products in the Environment

  • Gheorghe Duca
  • Veaceslav Boldescu
Part of the NATO Science for Peace and Security Series C: Environmental Security book series (NAPSC)


Various problems concerning the pharmaceutical and personal care products (PPCPs) in the environment of the Eastern European countries are described. The main classes of PPCPs in the environment, as well as major occurrence pathways and PPCPs fate, are depicted. The influence of specifics of the regional pharmaceutical market, medication consumption culture and pharmaceutical waste disposal techniques on environmental pollution with PPCPs, are discussed. Examples of wrong drugs prescription, drugs misuse, drugs overconsumption, and poor pharmaceutical waste management are presented. The necessity in research and management of PPCPs with emphasize on the local specifics and practices are concluded.


PPCPs pharmaceuticals personal care products drugs overconsumption drugs prescription pharmaceutical waste 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haling-Sørensen B, Nilesen N, Lanzky P F, et al. (1998) Occurrence, fate and effects of pharmaceutical substances in the environment — a review. Chemosphere 36: 357–393.CrossRefGoogle Scholar
  2. 2.
    Kolpin D A, Furlong E T, Meyer M T, et al. (2002) Pharmaceuticals, hormones, and other wastewater organic contaminants in U.S. streams 1999–2000 — a National reconnaissance. Env Sci Tech 36(6): 1202–1211.CrossRefGoogle Scholar
  3. 3.
    Jones O A H, Voulvoulis N, Lester J N (2002) Aquatic environmental assessment of the top 25 English prescription pharmaceuticals. Water Res 36(20): 5013–5022.CrossRefGoogle Scholar
  4. 4.
    US EPA (1997) Method 1694: Pharmaceuticals and personal care products in water, soil, sediment, and biosolids by HPLC/MS/MS. files/1694.pdf. Accessed 23 November 2008.
  5. 5.
    US EPA (1997) Method 1698: Steroids and hormones in water, soil, sediment, and bio-solids by HRGC/HRMS. Accessed 23 November 2008.
  6. 6.
    Daughton C G (2008) Pharmaceuticals as environmental pollutants: the ramifications for human exposure. In: Heggenhougen K and Quah S (eds.), International Encyclopedia of Public Health, Vol. 5. Academic Press, San Diego: pp. 66–102.CrossRefGoogle Scholar
  7. 7.
    Daughton C G (2007). Pharmaceuticals in the environment: sources and their management. Petrovic J and Barcelo D (eds.), Analysis, Fate and Removal of Pharmaceuticals in the Water Cycle, Elsevier Science, Barcelona: pp. 1–58.CrossRefGoogle Scholar
  8. 8.
    Anisimova O S, Frolova L V, Chistyakov V V, et al. (1995) Study of metabolism of the antiviral drug arbidol by mass spectrometry, thin-layer and high-performance liquid chro-matography. J Pharm Chem 29(2): 78–82.CrossRefGoogle Scholar
  9. 9.
    Wang Y, Chen X, Li Q, Zhong D (2008) Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry. J Mass Spectrom 43(8): 1099–1110.CrossRefGoogle Scholar
  10. 10.
    Manchand P S, Cerruti R L, Martin J A, et al. (1990) Synthesis and antiviral activity of metabolites of rimantadine. J Med Chem 33(7): 1992–1995.CrossRefGoogle Scholar
  11. 11.
    Bolaji O O, Onyeji C O, Ogundaini A O, et al. (1996) Pharmacokinetics and bioavailability of drotaverine in humans. Eur J Drug Metab Pharmacokinet 21(3): 217–221.CrossRefGoogle Scholar
  12. 12.
    Magyar K, Lengyel M, Knoll J (1978) Absorption, distribution and elimination of drotaverine. Acta Physiol Acad Sci Hun 51(4): 401–411.Google Scholar
  13. 13.
    Müssig K, Pfäfflin A, Häring H-U, Schleicher E D (2006) Dipyrone (metamizole) metabolites interfere with HPLC analysis of plasma catecholamines but not with the determination of urinary catecholamines. Clin Chem 52: 1829–1831.CrossRefGoogle Scholar
  14. 14.
    Vlahov V, Badian M, Verho M, Bacracheva N (1990) Pharmacokinetics of metamizole metabolites in healthy subjects after a single oral dose of metamizole. Eur J Clin Pharmacol 38(1): 61–65.CrossRefGoogle Scholar
  15. 15.
    Feldmann D F, Zuehlke S, Heberer T (2008) Occurrence, fate and assessment of polar metamizole (dipyrone) residues in hospital and municipal wastewater. Chemosphere 71(9): 1754–1764.CrossRefGoogle Scholar
  16. 16.
    Bobkov Iu G, Morozov I S, Glozman O M, et al. (1983) Pharmacological characteristics of a new phenyl analog of piracetam – 4-phenylpiracetam [article in Russian]. Biull EkspBiol Med 95(4): 50–53.Google Scholar
  17. 17.
    Stratchounski L S, Andreeva I V, Ratchina S A, et al. (2003) The inventory of antibiotics in Russian home medicine cabinets. Clin Infect Dis 37(4): 498–505.CrossRefGoogle Scholar
  18. 18.
    Olczac A, Grzesiowski P, Hryniewicz W, Haaijer-Ruskamp F M (2006) Self-medication with antibiotics in Poland. Pol Merkur Lekarski 20(116): 151–154.Google Scholar
  19. 19.
    Sanz E J, Hernandez M A, Ratchina S, et al. (2005) Prescribers' indications for drugs in childhood: a survey of five European countries (Spains, France, Bulgaria, Slovakia and Russia). Acta Paediatr 94(12): 1784–1790.CrossRefGoogle Scholar
  20. 20.
    Zarocostas J (2007) Misuse of prescription drugs could soon exceed that of illicit narcotics, UN panel warns. Br Med J 334(7591): 444.CrossRefGoogle Scholar
  21. 21.
    Marincovic N, Vitale K, Afrik I, Janev Holcer N (2005) Hazardous medical waste management as a public health issue. Arh Hig Rada Toksikol 56(1): 21–32.Google Scholar
  22. 22.
    Marinkovic N, Vitale K, Holcer N J, Dzakula A, Pavic T (2008) Management of hazardous medical waste in Croatia. Waste Manag 28(6): 1049–1056.CrossRefGoogle Scholar
  23. 23.
    Osipova T V, Kolpashchikova I F, Smirenskaia L Iu, et al. (2007) Medical waste the problem of handling [article in Russian]. Gig Sanit 2: 15–17.Google Scholar
  24. 24.
    Stanković A (2008) Report: treatment of medical waste in Nišava and Toplica districts, Serbia. Waste Manag Res 26(3): 309–313.CrossRefGoogle Scholar
  25. 25.
    Moldovan Z (2006) Occurrences of pharmaceutical and personal care products as micropol-lutants in rivers from Romania. Chemosphere 64(11): 1808–1817.CrossRefGoogle Scholar
  26. 26.
    Moldovan Z, Schmutzer G, Tusa F, et al. (2007) An overview of pharmaceuticals and personal care products contamination along the river Somes watershed, Romania. J Environ Monit 9(9): 986–993.CrossRefGoogle Scholar
  27. 27.
    Moller P, Paces T, Dulski P, Morteani G (2002) Anthropogenic Gd in surface water, drainage system, and the water supply of the city of Prague, Czech Republic. Environ Sci Tech-nol 36(11): 2387–2394.CrossRefGoogle Scholar
  28. 28.
    Morteani G, Moller P, Fuganti A, Paces T (2006) Input and fate of anthropogenic estrogens and gadolinium in surface water and sewage plants in the hydrological basin of Prague (Czech Republic). Environ Geochem Health 28(3): 257–264.CrossRefGoogle Scholar
  29. 29.
    Kasprzyk-Hordern B, Dabrowska A, Vieno N, et al. (2008) Occurrence of acidic pharmaceuticals in the Warta river in Poland. Chem Anal 53(2): 289–303.Google Scholar
  30. 30.
    Sajewicz M (2005) Use of densitometric TLC for detection of selected drugs present in river water in south Poland. J Planar Chromatogr — Modern TLC 18(102): 108–111.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  1. 1.Department of Industrial and Ecological ChemistryState University of MoldovaChisinauRepublic of Moldova

Personalised recommendations